| Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. | |
| | |
MedLine Citation:
|
PMID: 21199265 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
AIM: colesevelam is indicated to lower low density lipoprotein cholesterol (LDL-C) in hyperlipidaemia and improve glycaemic control in adults with type 2 diabetes. This short-term pilot study evaluates its effects in type 1 diabetes. METHODS: this double-blind, randomized, investigator-initiated, single-centred, 12-week pilot study evaluated 40 adults (age = 36.4 ± 9.4 years) with type 1 diabetes (duration = 20.4 ± 8.5 years) and hyperlipidaemia. It was powered to show a treatment difference of >10% LDL-C reduction. Subjects received 3.75 g/day colesevelam (n = 20) or placebo (n = 20) for 12 weeks. LDL-C and haemoglobin A1c (A1c) levels were assessed at screening (week 2), baseline (week 0) and every 4 weeks throughout the treatment duration. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) levels were measured during 4-h meal (Boost Plus, Nestle HealthCare Nutrition Inc., Florham Park, New Jersey, USA) challenge tests (MCT) at baseline and 12 weeks. RESULTS: colesevelam treatment resulted in a significant reduction in LDL-C values at 4 weeks [-12.1% (95% CI: -20.1 to -4.1), p = 0.004] which was sustained for the study duration (p = 0.005 at 12 weeks). The treatment group also showed a significant change in A1c from baseline at week 4; however, this was not significant for the study duration. There was a significant median increase in GLP-1 levels during the first 2 h of the baseline MCT in the treated group but no difference at 12 weeks. CONCLUSIONS: during this short-term pilot study, colesevelam treatment effectively lowered LDL-C in patients with type 1 diabetes. Improvements in A1c seen at week 4 were not sustained. Effects on glycaemic control in subjects with type 1 diabetes may be related to a postprandial rise in GLP-1 levels and require further clinical study. |
| | |
Authors:
|
S K Garg; P J Ritchie; E G Moser; J K Snell-Bergeon; B J Freson; R M Hazenfield |
Related Documents
:
|
19279655 - An endoluminal sleeve induces substantial weight loss and normalizes glucose homeostasi... 1569155 - Does aging intensify the insulin resistance of human obesity? 18855625 - Gpr40 carboxylic acid receptor family and diabetes: a new drug target. 19914095 - Increasing bmi and waist circumference and prevalence of obesity among adults with type... 15723895 - Evaluation of the ucl diabetes self-management programme (ucl-dsmp): a randomized contr... 12756495 - Fibromyalgia in diabetes mellitus. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 13 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-04 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 137-43 Citation Subset: IM |
Affiliation:
|
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Aurora, CO 80045, USA. satish.garg@ucdenver.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fuelling the athlete with type 1 diabetes.
Next Document: Patient perspectives on once-weekly medications for diabetes.